Alvine Pharmaceuticals, Inc.' ALV003 Named a Top 10 Inflammatory/Autoimmune Project to Watch by Windhover Information Inc.

Published: Nov 02, 2010

SAN CARLOS, Calif.--(BUSINESS WIRE)--Alvine Pharmaceuticals, Inc., a leader in celiac disease therapeutics, announced today that the company’s lead therapeutic product candidate, ALV003, has been selected by Windhover and its advisors as one of “The Top 10 Inflammatory/Autoimmune Projects to Watch.” Windhover is a leading provider of business information to senior executives in the pharmaceutical, biotechnology and medical device industries. Alvine has been invited to present at Windhover’s Therapeutic Area Partnerships Conference on November 3, 2010 in Boston, MA.

Back to news